Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Atria Investments Inc

Atria Investments Inc lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,953 shares of the company’s stock after selling 6,903 shares during the period. Atria Investments Inc’s holdings in Teva Pharmaceutical Industries were worth $528,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assetmark Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 1,370.3% during the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock worth $115,000 after buying an additional 4,851 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 56.8% during the fourth quarter. Victory Capital Management Inc. now owns 3,023,474 shares of the company’s stock worth $66,637,000 after buying an additional 1,094,759 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 14.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,028,924 shares of the company’s stock worth $22,677,000 after buying an additional 129,749 shares during the last quarter. LGT Fund Management Co Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $3,558,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.5 %

Shares of Teva Pharmaceutical Industries stock opened at $16.38 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The company has a market capitalization of $18.57 billion, a P/E ratio of -11.29, a P/E/G ratio of 1.44 and a beta of 0.82. The business has a 50 day moving average price of $18.28 and a 200 day moving average price of $18.29.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.55% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on TEVA. Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, March 7th. Finally, UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.